How the once-dominant cancer company has overhauled its strategy for long-term growth

Plus: Readouts from Sanofi-Teva, Bicycle and more

In BioCentury’s Public Equity Report: Oncology companies tap public markets for more than $1.2B, while Olema draws $250M PIPE for Novartis combo trial

Plus: Denmark-based Pharmacosmos buys G1, obtaining myelosuppression drug

Week's deals also include a radionuclide conjugate partnership between SK and Full-Life, and GT Apeiron hands off CDK7 to Exscientia

Plus: New data from Wave, G1 and Jazz

Plus: Results from Lilly’s Verzenio, antibody-drug conjugate Enhertu, and programs from Newron and Annovis

AACR abstracts highlight CDK2 inhibition as solution to CDK4/6 resistance and route to reaching more cancer types

Plus: BioNTech, OncoC4 build case for CTLA-4 product with lung cancer readout, and updates from Takeda, Poseida, Canbridge and more

Plus: SR One closes $600M second fund and updates from Vertex, CRISPR; Merck KGaA, Pfizer and more